Commercial Due Diligence for Biotechnology Decisions
Look beyond the forecast. Understand what must actually happen for the commercial opportunity to become real.
Beyond the Forecast
A promising clinical asset does not automatically represent an equally attractive commercial opportunity.
Commercial due diligence should evaluate the assumptions connecting scientific innovation to real-world adoption. PharmaKonsult provides an experienced commercial perspective for biotechnology leadership teams, boards and investors evaluating assets, commercialization strategies and strategic decisions.
Questions Commercial Due Diligence Should Answer
Is the addressable patient population realistic?
Published prevalence is only the beginning—diagnosed population, diagnosis rate, eligible population, treatment rate, referral patterns and geographic accessibility.
Who actually controls adoption?
Specialists, institutions, referral networks, payers, pharmacy channels, patient services, caregivers and advocacy organizations.
Is the competitive position credible?
Existing therapies, development-stage competitors, switching barriers, physician habits, treatment guidelines, differentiation and evidence requirements.
Can patients realistically access therapy?
Reimbursement complexity, prior authorization, distribution, specialty pharmacy, affordability and patient support.
Is the commercialization plan feasible?
Capabilities, leadership, organization, timelines, investment requirements, commercial infrastructure and execution risk.
Who May Benefit
- CEOs
- boards
- biotechnology investors
- venture firms
- companies considering licensing opportunities
- organizations assessing potential acquisitions
- companies deciding whether to commercialize independently
Commercial diligence should not be designed to prove an investment thesis. Its purpose is to pressure-test it.
Related: Board & Investor Commercial Advisory.
Evaluating a biotechnology commercial opportunity?
Discuss the commercial assumptions with PharmaKonsult.
